Skip to main content

Table 6 shows relevant metrics prostate and organs at risk for prescription doses of 35 Gy to the prostate and 42 Gy to the intraprostatic tumor mass in 5 fractions. Median and interquartile ranges are shown

From: Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients

  Prostate volume Boost volume (absolut / % of prostate volume) PTV prostate PTV boost volume Bladder Rectum Urethra
Prescition dose (Prostate/Boost)   D98% D50% D98% D0.03cc D15% D0.03cc D2cc D20% D0.01cc D50%
35/42 Gy 34.5
(29.3–42-5)
13.2 (8.3–21.1) / 32 (28–55) 33.8
(33.4–33.9)
42.4
(42–42.5)
39.3
(38.3–39.9)
36.1
(35.1–36.6)
20.2
(17.3–22.2)
37.1
(36.4–37.8)
34.8
(32.7–34.8)
18.9
(16.0–21.0)
39.8
(39.5–40.2)
35.7
(35.7–36.4)